spacer
home > pmps > summer 2017 > track your progress
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Track Your Progress

While serialisation in the pharmaceutical supply chain is generally regarded as inevitable – counterfeiting is simply too large of a problem to not be addressed – some uncertainty around the specifics exists, particularly from a global position. Regulations are advancing at various speeds around the world, and, to date, global standards as to how serial numbers should be formatted have not emerged.

Progressing Through Uncertainty

This has demanded that manufacturers move forward cautiously in their approach to serialisation. They must take steps to prepare without committing themselves to technologies that may not support future requirements. To that end, many have placed systems necessary to apply and capture serialisation data in their packaging processes, but have, in general, not addressed the impact of tracking these numbers across the supply chain.

This is partly due to the nature of a typical pharma supply chain, which is more dependent on third-party logistics providers for downstream processes than other industries. These providers enable companies to minimise supply chain assets and focus their capital on R&D, but they tend to limit their investments in automation because short-term contracts do not allow a return on investment within the contract period.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Michiel Veenman, Global Market Leader at Swisslog Warehouse and Distribution Solutions, has worked with various pharma companies to design advanced intralogistics solutions prior to taking on his current role. As such, he is responsible for continuously improving the company’s contribution to the market. This includes market research, organisational development and training and solution design, as well as systems support. Having studied logistics, Michiel has experience working for the Dutch Department of Defense and in automation system simulation and analysis. Before joining Swisslog, he spent five years optimising warehouse operations and IT systems for a small veterinarian pharma wholesaler.
spacer
Michiel Veenman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Extremely fast chemical search in vast chemical space

Read through a poster by ChemAxon aiming to find novel analogues of known drugs among the 977 million unique entries of the GDB-13 database. The result got queried against the SureChEMBL's patent database as well.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

SMi presents the 13th Conference on ADMET

9-10 July 2018, Holiday Inn Kensington Forum, London, UK

SMi is delighted to announce the 13th annual ADMET conference returning to London to explore the optimisation of ADMET modelling techniques, preclinical DMPK applications and development of biopharmaceuticals.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement